Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
2006-05-02
2006-05-02
McKenzie, Thomas C. (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitrogen attached directly or indirectly to the purine ring...
C514S266400
Reexamination Certificate
active
07038049
ABSTRACT:
The present disclosure includes compounds, for example a compound according to formula Ior a pharmaceutically acceptable salt thereof. The compounds of the present disclosure are useful in methods of treating cancerous conditions.
REFERENCES:
patent: 4343940 (1982-08-01), Kreighbaum et al.
patent: 4559157 (1985-12-01), Smith et al.
patent: 4608392 (1986-08-01), Jacquet et al.
patent: 4820508 (1989-04-01), Wortzman
patent: 4938949 (1990-07-01), Borch et al.
patent: 4992478 (1991-02-01), Geria
patent: 5457105 (1995-10-01), Barker
patent: 5480883 (1996-01-01), Spada et al.
patent: 5710158 (1998-01-01), Myers et al.
patent: 5712395 (1998-01-01), App et al.
patent: 5721237 (1998-02-01), Myers et al.
patent: 5747498 (1998-05-01), Schnur et al.
patent: 5773476 (1998-06-01), Chen et al.
patent: 5792771 (1998-08-01), App et al.
patent: 5821246 (1998-10-01), Brown et al.
patent: 6004967 (1999-12-01), McMahon et al.
patent: 6184225 (2001-02-01), Thomas et al.
patent: 6258820 (2001-07-01), Uckun et al.
patent: 6358962 (2002-03-01), Uckun et al.
patent: 29 36 705 (1980-03-01), None
patent: 0 566 226 (1993-10-01), None
patent: WO 95/15758 (1995-06-01), None
patent: WO 95/21613 (1995-08-01), None
patent: WO 96/09294 (1996-03-01), None
patent: WO 96/15118 (1996-05-01), None
patent: WO 96/40648 (1996-12-01), None
patent: WO 97/30035 (1997-08-01), None
patent: WO 97/32856 (1997-09-01), None
patent: WO 98/10767 (1998-03-01), None
patent: WO 99/61428 (1999-12-01), None
Bridge, Alexander J.; Zhou, Hairong; Cody, Donna R.; Rewcastle, Gordon W.; McMichael, Amy; Showalter, H. D. Hollis; Fry, David W.; Kraker, Alan J.; Denny, William A., J. Med. Chem., 39(1), 267-76 (English) 1996.
Singh, P.; Kumar, R. Journal of Enzyme Inhibition, 13(2), 125-134 (English) 1998.
Gazit, Aviv; Chen, Jeffrey; App, Harald; McMahon, Gerald; Hirth, Peter; Chen, Irit; Levitzki, Alexander, Bioorganic & Medicinal Chemistry, 4(8), 1203-1207, 1996.
Bridges, A. et al., “Tyrosine Kinase Inhibitors. 8. An Unusually Steep Structure-Activity Relationship for Analogues of 4-(3-Bromoanilino)-6, 7-dimethoxyquinazoline (PD 153035), a Potent Inhibitor of the Epidermal Growth Factor Receptor”,Journal of Medicinal Chemistry,vol. 39, pp. 267-276 (Jan. 19, 1996).
Budesinsky, Z. et al., “A New Synthesis of the Quinazoline Nucleus”,Collection of Czechoslovak Chemical Communications,vol. 37, No. 8, pp. 2779-2785 (Aug. 1972).
Fetter, J. et al., “Electron Deficient Heteroaromatic Ammonioamidates-XVI, The Synthesis and Photochemistry of Ethyl N-(2-Methyl-4-Methylene-6, 7-Methylenedioxy-3, 4-Dihydro-3-Quinazolinyl)-N-Phenylcarbamate”,Tetrahedron,vol. 34, pp. 2557-2563 (1978).
Goodman, P. et al., “Role of Tyrosine Kinases in Induction of the c-jun Proto-oncogene in Irradiated B-lineage Lymphoid Cells”,The Journal of Biological Chemistry,vol. 273, No. 28, pp. 17742-17748 (Jul. 10, 1998).
Hatva, E. et al., “Expression of Endothelial Cell-Specific Receptor Tyrosine Kinases and Growth Factors in Human Brain Tumors,”Amer. Journal of Pathology,vol. 146, No. 2, pp. 368-378 (Feb. 1995).
Hennequin, L. et al.,Journal of Medicinal Chemistry,vol. 42, No. 26, pp. 5369-5389 (1999).
Higashino, T. et al. “Reactions of the anion of quinazoline Reissert compound (3-benzoyl-3, 4-dihydro-4-quinazolinecarbon itrile) with electophiles”,Chemical&Pharmaceutical Bulletin,vol. 33, No. 3, pp. 950-961 (Mar. 1985).
Ife, R. et al., “Reversible Inhibitors of the Gastric (H+/K+)-ATPase”,Journal of Medicinal Chemistry,vol. 38, No. 14, pp. 2763-2773 (Jul. 7, 1995).
Kubo, K. et al., “A Novel Series of 4-Phenoxyquinolines: Potent and Highly Selective Inhibitors of PDGF Receptor Autophosphorylation”,Bioorganic&Medicinal Chemistry Letters,vol. 7, No. 23, pp. 2935-1940 (Dec. 2, 1997).
Lempert-Sreter, M. et al., “Electron deficient heteroaromatic ammonioamidates,”Chem. Abstract,vol. 93, entry 150203, 1 page (1980).
Malaviya, R et al., “Genetic and Biochemical Evidence for a Critical Role of Janus Kinase (JAK)-3 in Mast Cell-Mediated Type 1 Hypersensitivity Reactions”,Biochemical and Biophysical Research Communications,vol. 257, No. 3, pp. 807-813 (Apr. 21, 1999).
Miyashita, A. et al., “Catalytic Action of Azolium Salts. II” Aroylation of 4-Chloroquinazolines with Aromatic Aldehydes Catalyzed by 1,3-Dimethylbenzimidazolium lodide,Chem. Pharm. Bull.vol. 40, No. 1, pp. 43-48 (Jan. 1992).
Miyashita, A. et al., “An Approach to the Synthesis of a Papaverine Analogue Containing a Quinazoline Ring System,”Heterocycles,vol. 40, No. 2 pp. 653-660 (1995).
Miyashita, A. et al., “Several approaches to cyanide ion-catalyzed synthesis of 4-aroyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidines,”Chem. Abstract,vol. 128, entry 270579, 1 page (1998).
Myers, M. R. et al., “The Preparation and SAR of 4-(Anilino), 4-(Phenoxy), and 4-(Thiopenoxy)-Quinazolines: Inhibitors of p56 nd EGF-R Tyrosine Kinase Activity,”Bioorganic &Medicinal Chemistry Letters,vol. 7, No. 4, pp. 417-420 (1997).
Narla, R. K. et al., “4-(3′-Bromo-4′ hydroxylphenyl)-amino-6, 7-dimethoxyquinazoline: A Novel Quinazoline Derivative with Potent Cytotoxic Activity against Human Glioblastoma Cells,”Clinical Cancer Research,vol. 4, pp. 1405-1414 (Jun. 1998).
Narla, R. K., et al., Inhibition of Human Glioblastoma Cell Adhesion and Invasion by 4-(4′-Hydroxylphenyl)-amino-6, 7-dimethoxyquinazoline (WHI-P131) and 4-(3′-Bromo-4′-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WH1-P154),Clinical Cancer Research,vol. 4, No. 10, pp. 2463-2471 (Oct. 1998).
Nomoto, Y. et al., “Studies on Cardiotonic Agents. I. Synthesis of Some Quinazoline Derivatives,”Chem. Pharm. Bull.,vol. 38, No. 6, pp. 1591-1595 (1990).
Porrizas, M. et al.,Endocrinology,vol. 138, No. 4, pp. 1427-1433 (1997).
Suzuki, Y. et al., “Carbon-carbon bond cleavage of alpha -hydroxybenzylheteroarenes catalyzed,”Chem. Abstract,vol. 128, entry 230337, 5 pages (1998).
Taylor, E. C. et al., “General procedure for the syntheisis of epoxyalkylated and acylated heterocycles,”Chem. Abstract,vol. 93, entry 47718, 2 pages (1974).
Zagzag, D. “Angiogenic Growth Factors in Neural Embryogenesis and Neoplasia,”Amer. Journal of Pathology,vol. 146, No. 2, pp. 293-309 (Feb. 1995).
Liu Xing-Ping
Narla Rama Krishna
Uckun Fatih M.
Haack John L.
Kettleberger Denise M.
McKenzie Thomas C.
Merchant & Gould P,C,
Parker Hughes Institute
LandOfFree
Haloanilino quinazolines and therapeutic use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Haloanilino quinazolines and therapeutic use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Haloanilino quinazolines and therapeutic use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3561135